Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christof Scheid

Showing results (81-90 of 200) with videos related to

Pageof 20
Sort By:
Blood Advances|March 27, 2026
Idecabtagene vicleucel manufacturing and clinical value of out of specification products in relapsed and refractory MMSurbhi Sidana, Yi Lin, Andrew J Cowan, et al.
Haematologica|January 5, 2023
Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosisClaire Harrison, Abdulraheem Yacoub, Bart Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2012
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remissionSebastian Theurich, Joke Malcher, Kerstin Wennhold, et al.
Leukemia & Lymphoma|May 6, 2014
Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphomaChristian Straka, Hans Salwender, Brigitte Schnabel, et al.
Blood|July 19, 2017
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trialIsabelle Krämer, Stephan Stilgenbauer, Sascha Dietrich, et al.
Frontiers in Oncology|October 8, 2024
How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspectiveAnn-Cathrine Siefen, Melina Sophie Kurte, Florian Jakobs, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Genes, Chromosomes & Cancer|April 29, 2014
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasmsDarko Gosenca, Beate Kellert, Georgia Metzgeroth, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 15, 2014
Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunityAlexander Shimabukuro-Vornhagen, Shahram Zoghi, Tanja M Liebig, et al.
Leukemia & Lymphoma|September 22, 2016
Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meetingLaurent Garderet, Gordon Cook, Holger W Auner, et al.
Pageof 20

Showing results (81-90 of 200) with videos related to

Sort By:
Pageof 20
Blood Advances|March 27, 2026
Idecabtagene vicleucel manufacturing and clinical value of out of specification products in relapsed and refractory MMSurbhi Sidana, Yi Lin, Andrew J Cowan, et al.
Haematologica|January 5, 2023
Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosisClaire Harrison, Abdulraheem Yacoub, Bart Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2012
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remissionSebastian Theurich, Joke Malcher, Kerstin Wennhold, et al.
Leukemia & Lymphoma|May 6, 2014
Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphomaChristian Straka, Hans Salwender, Brigitte Schnabel, et al.
Blood|July 19, 2017
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trialIsabelle Krämer, Stephan Stilgenbauer, Sascha Dietrich, et al.
Frontiers in Oncology|October 8, 2024
How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspectiveAnn-Cathrine Siefen, Melina Sophie Kurte, Florian Jakobs, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Genes, Chromosomes & Cancer|April 29, 2014
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasmsDarko Gosenca, Beate Kellert, Georgia Metzgeroth, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 15, 2014
Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunityAlexander Shimabukuro-Vornhagen, Shahram Zoghi, Tanja M Liebig, et al.
Leukemia & Lymphoma|September 22, 2016
Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meetingLaurent Garderet, Gordon Cook, Holger W Auner, et al.
Pageof 20